Reply  by Jones, James W. et al.
The broad public record on AneuRx (including the FDA’s
Public Health Notifications), combined with the experience of
more than 40,000 patients in the United States, confirm that
AneuRx is a safe, effective, and important treatment option for
adults with potentially deadly abdominal aortic aneurysms. As
reported in Medtronic’s 2004 clinical update, US clinical results
from a total of 1193 patients (using Kaplan-Meier analyses) at 5
years are as follows:
● freedom from rupture rate of 97.2%
● freedom from surgical conversion rate of 91.1%
● freedom from aneurysm-related death rate of 96.8%
● probability of survival rate, based on all-cause mortality, of
61.5%
Going forward, Medtronic will continue to act, as necessary,
to ensure that our proprietary clinical data are used appropriately
and interpreted properly in the public domain.
We thank those clinical researchers who have had the vision
and drive to develop new and less invasive therapies for abdominal
aortic aneurysms, and we remain committed to restoring health
and extending life for the thousands of patients with this life-
threatening disease.
Stephen N. Oesterle, MD
Senior Vice President of Medicine and Technology
Medtronic, Inc
Minneapolis, Minn
doi:10.1016/j.jvs.2004.08.011
Regarding “Ethics of boutique medical practice”
The article in the June issue of the Journal by Jones et al
entitled “Ethics of boutique medical practice” (J Vasc Surg 2004;
39:1354-5) raises timely and important ethical issues that physi-
cians and health care consumers need to analyze and confront. We
would like to address a number of points made in the article that
could serve as a further basis for discussion on providing this type
of care.
It is noteworthy that Jones alleges that “boutique practice
reduces medicine to a commodity, unacceptably diminishing pro-
fessionalism” (italics added). From an economic standpoint, a
commodity is a type of service or product that is undifferentiated
and can be readily replicated. Indeed, their ready availability is the
reason why most commodity services are very price-elastic and
therefore relatively inexpensive. Consumers are not willing to pay
higher prices for services that are easily copied and are not distin-
guished by the quality of the provider of such services (such as dry
cleaners). What physicians are attempting to do by providing
boutique medicine is to differentiate themselves in the marketplace
by providing perceived specialized services. Ethical or not, the
result is not medicine as a commodity; if anything, boutique
medicine provides a highly differentiated product and service that
lies far from the definition of an economic commodity.
Perhaps this differentiation is what leads Jones to suggest that
a boutique medical practice will result in a 2-tiered system of
medicine. Arguably, the US health care system is already multit-
iered, with an increasing number of underinsured health care
recipients (including Medicare recipients without supplemental
coverage) being added to the dichotomy of fully insured and
uninsured populations.1 Levels of care and access to appropriate
services correlate to some degree to the “tier”; boutique medicine
likely represents a fourth level of health care access. As Uwe
Reinhardt2 has noted, concierge medicine is not qualitatively
different from limiting insurance participation; it is just a creative
extension of limiting care by class to improve profits.
Finally, one must wonder about the economic feasibility of
providing boutique surgical services. These services, unlike those
provided in primary care, are quite episodic; a patient may, in fact,
not need such services for decades. It seems highly unlikely that
patients would therefore pay a retainer for boutique surgical care.
Concierge care may in fact be unethical. It does not, however,
reduce medicine to a commodity and is fundamentally no different
from physicians’ refusal to participate in low-paying insurance
plans, such as Medicaid. Analysis of the ethics of a boutique
medical practice should lead providers and consumers to a reap-
praisal of the national US health care system. And at any rate,
concierge surgical care may be only of academic concern. Very
likely, there will not be much of a market for it.
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Reply
We thank Drs Akbari and Henochowicz for their comments
on our critique of boutique medical practice. Our criticisms of the
practice were based on a concept at the core of medical ethics, the
physician as the patient’s fiduciary. We argued that the commodity
typically sold in these premium-priced programs—special access to
the physician’s care—serves the economic self-interest of physi-
cians without offering any improvement in the quality of care to be
provided, and inevitably does so by making physician access more
difficult for the clinic’s patients who have not elected to pay the
premium for the first-class plan. Drs Akbari and Henochowicz
appear not to contest this formulation, and concentrate their
objections upon alternative definitions of the term commodity, for
which they provide a description of the sort normally associated
with economic discourse.
This objection involves a pair of significant and related errors.
The first is that economic definitions and values outweigh all other
considerations, but Drs Akbari and Henochowicz provide no
argument to support this view. With their first mistaken assump-
tion unsupported, the second is something of an inevitability: a
specious reductionism in the economic definition of “commodity”
to its differentiation, which overlooks the word’s historical sense.
“Commodity” shares its etymology with “accommodate” and,
curiously, “commode.” “A commodity was a convenience, then an
opportunity, then an advantage, then a thing to sell at an advan-
tage, merchandise.”1 The authoritative dictionaries variously de-
fine commodities as economic goods, articles of commerce, things
useful or valued subject to ready exchange or exploitation within a
market; or as a mass-produced unspecialized product, an economic
unit useful in manufacturing.
Drs. Akbari and Henochowicz’s contention that “from an
economic standpoint, a commodity is a type of service or product
which is undifferentiated and can be readily replicated” is true, but
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inessential to the term’s definition, and therefore not pertinent to
our argument. The readiness of reproduction being equated with
differentiation and market elasticity are loosely stated principles of
economics, not the definition of commodity. Reducing medical
care to the status of a commodity, the objection we find in
boutique medicine, makes the practice of medicine a purely com-
mercial transaction. Whether that transaction involves a differenti-
ated or undifferentiated good or service is ethically irrelevant to our
argument that doing so undermines medical professionalism.
Our article did not predict a 2-tiered medical system emerging
from the boutique model; we did intimate that it could result in a
2-tiered individual practice among physicians who adopt it. Our
objection to this is that it would result in physicians who engage in
boutique medicine treating the rich and poor differently, which,
Dr Gregory pointed out more than 2 centuries ago, violates
fiduciary professionalism. VIP medicine is arranged and adminis-
tered by the individual physician; the tiers are within his practice.
The easier access and closer observation he provides his premium-
fee patients necessarily means that all other patientss are receiving
less than his best efforts and attention. A multitiered medical system
follows when these individual practices grease the slope toward
normalization of socially acceptable multitiered insurance benefits,
perhaps a boutique policy for the company’s top executives and a
“standard plan” for the folks on the assembly line. The quality,
quantity, and accessibility of medical care may show a normal range
of variation consistent with skills and resources from 1 institution
or physician to another. The systemization of these variations
becomes unethical, however, when they occur within a structure
that offers the physician special incentives to stratify the quality of
care on the basis of the patient’s ability to pay, or willingness to pay
an inflated premium, as in our boutique model. Drs Akbari and
Henochowicz conclude that boutique medicine is ethically neu-
tral, with doctors merely attempting “to differentiate themselves in
the marketplace by providing perceived specialized services.”
Boutique medicine does not differentiate the physicians, it
differentiates the patients—and in so doing becomes ethically
unpalatable. Drs Akbari and Henochowicz prefer “concierge” to
“boutique” medicine. Neither of these terms of commerce reflects
the special responsibilities of the medical professional, or the
absolute trust with which every patient approaches his physician.
Drs Akbari and Henochowicz have accurately described a “com-
modity” in economic discourse; if physicians begin to associate it
with their patients, the “medical profession” will become an oxy-
moron.
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Regarding “Standards of practice: Carotid
angioplasty and stenting”
We appreciate Ouriel et al’s commentary (J Vasc Surg 2004;
39:916-7) highlighting the quality improvement guidelines for the
performance of cervical carotid angioplasty and stent placement.1
We wish to clarify that the radiology guidelines provide a
training pathway for physicians with experience sufficient to meet
the American Heart Association requirements for peripheral vas-
cular interventions, this being prior experience of 100 diagnostic
cervicocerebral angiograms with documented acceptable indica-
tions and outcomes.1,2 In agreement with previous recommenda-
tions by the American Heart Association, regardless of the number
of angiograms in another vascular bed, each vascular bed is distinct
and 100 angiograms are necessary.2
We agree with the authors that carotid stenting is a dynamic
area. As stated in our guidelines, the document was developed on
the basis of evidence-based literature. As additional peer-reviewed
studies are published, we look forward to working with all inter-
ested specialties to refine these guidelines in order to ensure
excellence in patient care. We have long recognized the valuable
impact that multidisciplinary documents have in the improvement
of patient safety and patient care outcomes.
We agree that clinical trial data are important for evaluating
new technology. However, as noted in the commentary of Ouriel
et al., some procedures prematurely become widely accepted be-
fore convincing evidence is available. In these circumstances, a
consensus statement summarizing the available evidence-based
recommendations for treatment is valuable. For example, experi-
ence has demonstrated that while benefit seemed “intuitively
clear” for extracranial-intracranial bypass surgery for carotid and
intracranial atherosclerosis, true clinical trial data led to the demise
of this procedure.3 Additionally, for 4 decades warfarin was
“thought to be” the “maximum medical therapy” for cerebrovas-
cular disease, but it was then proven that aspirin was as good as or
better than warfarin.4,5
The Society of Interventional Radiology and the American
Society of Interventional and Therapeutic Neuroradiology are
committed to working with industry and government to ensure
that appropriately selected patients have access to this beneficial
new technology. In addition to guideline development, we will
work with other specialties to ensure future coverage by Centers
for Medicare and Medicaid Services. We look forward to working
with all those involved in carotid stenting to further develop and
evaluate this important new technology.
Janette D. Durham, MD, MBA
President, Society of Interventional Radiology
University of Colorado Health Sciences Center
Denver, Colo
David Sacks, MD
Standards Division Councilor, Society of Interventional
Radiology
Reading Hospital
Reading, Pa
John J. Connors III, MD
President, American Society of Interventional and Therapeutic
Neuroradiology
Miami Cardiac and Vascular Institute
Miami, Fla
REFERENCES
1. Barr JD, Connors JJ III, Sacks D, Wojak JC, Becker GJ, Cardella JF, et al.
Quality improvement guidelines for the performance of cervical carotid
angioplasty and stent placement. Developed by a collaborative panel of
the American Society of Interventional and Therapeutic Neuroradiology,
the American Society of Neuroradiology, and the Society of Interven-
tional Radiology. J Vasc Interv Radiol 2003;14:1079-93.
2. Levin DC, Becker GJ, Dorros G, Goldstone J, King SB 3rd, Seeger JM,
et al. Training standards for physicians performing peripheral angioplasty
and other percutaneous peripheral vascular interventions. A statement for
health professionals from the Special Group of Councils on Cardiovas-
cular Radiology, Cardio-Thoracic and Vascular Surgery, and Clinical
Cardiology, American Heart Association. Circulation 1992;86:1348-50.
JOURNAL OF VASCULAR SURGERY
Volume 40, Number 4 Letters to the Editor 837
